Abstract

A program to detect defective drugs in the postmarketing period. Rev Panam Salud Publica [online]. 1999, vol.6, n.3, pp. 211-214. ISSN 1020-4989.  http://dx.doi.org/10.1590/S1020-49891999000800014.

Defective drugs have been found during the postmarketing phase in various countries, regardless of those nations' level of economic development. This paper proposes guidelines for a program to uncover drug defects in the postmarketing surveillance period. Such a program should be run by a center or service organized for that purpose within the framework of a national drug surveillance system.